Please confirm you are human (Sign Up for free to never see this)
← Back to Search
VISTA Is An Acidic PH-selective Ligand For PSGL-1
Robert J. Johnston, L. J. Su, J. Pinckney, D. Critton, E. Boyer, Arathi M Krishnakumar, M. Corbett, A. L. Rankin, Rose A. Dibella, L. Campbell, G. Martin, Hadia Lemar, T. Cayton, Richard Y.-C. Huang, X. Deng, A. Nayeem, Haibin Chen, B. Ergel, Joseph M. Rizzo, A. Yamniuk, S. Dutta, J. Ngo, A. Shorts, R. Ramakrishnan, Alexander Kozhich, J. Holloway, H. Fang, Ying-Kai Wang, Z. Yang, K. Thiam, G. Rakestraw, Arvind Rajpal, P. Sheppard, M. Quigley, K. Bahjat, A. Korman
Published 2019 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Co-inhibitory immune receptors can contribute to T cell dysfunction in patients with cancer1,2. Blocking antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) partially reverse this effect and are becoming standard of care in an increasing number of malignancies3. However, many of the other axes by which tumours become inhospitable to T cells are not fully understood. Here we report that V-domain immunoglobulin suppressor of T cell activation (VISTA) engages and suppresses T cells selectively at acidic pH such as that found in tumour microenvironments. Multiple histidine residues along the rim of the VISTA extracellular domain mediate binding to the adhesion and co-inhibitory receptor P-selectin glycoprotein ligand-1 (PSGL-1). Antibodies engineered to selectively bind and block this interaction in acidic environments were sufficient to reverse VISTA-mediated immune suppression in vivo. These findings identify a mechanism by which VISTA may engender resistance to anti-tumour immune responses, as well as an unexpectedly determinative role for pH in immune co-receptor engagement. V-domain immunoglobulin suppressor of T cell activation (VISTA) selectively engages P-selectin glycoprotein ligand-1 (PSGL-1) and suppresses T cells at acidic pH similar to those in tumour microenvironments, thereby mediating resistance to anti-tumour immune responses.
This paper references
P‐selectin glycoprotein ligand‐1 modulates immune inflammatory responses in the enteric lamina propria
Norman Nuñez-Andrade (2011)
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.
Roberto Tinoco (2016)
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
Insights into the Molecular Basis of Leukocyte Tethering and Rolling Revealed by Structures of P- and E-Selectin Bound to SLeX and PSGL-1
W. Somers (2000)
A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding
D. Sako (1995)
Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation.
R. M. Nelson (1993)
T Cell Dysfunction in Cancer.
D. Thommen (2018)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
P. Adams (2010)
Acidic extracellular microenvironment and cancer
Y. Kato (2013)
P-selectin glycoprotein ligand-1 in T cells
Michael Abadier (2017)
Considering protonation as a posttranslational modification regulating protein structure and function.
A. Schönichen (2013)
Cancer immunotherapy using checkpoint blockade
A. Ribas (2018)
Features and development of Coot
P. Emsley (2010)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
Regulatory T Cells Suppress the Late Phase of the Immune Response in Lymph Nodes through P-Selectin Glycoprotein Ligand-1
Stefano Angiari (2013)
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
J. Blando (2019)
Human antibodies from transgenic animals
N. Lønberg (2005)
Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein
T. Oliphant (2006)
VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis
S. Ceeraz (2017)
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
The relevance of tumour pH to the treatment of malignant disease.
J. Wike-Hooley (1984)
Direct identification of ligand-receptor interactions on living cells and tissues
Andreas P. Frei (2012)
Psoralen photo-crosslinked mRNA-puromycin conjugates: a novel template for the rapid and facile preparation of mRNA-protein fusions.
M. Kurz (2000)
RNA-peptide fusions for the in vitro selection of peptides and proteins.
R. Roberts (1997)
PSGL‐1 function in immunity and steady state homeostasis
D. Carlow (2009)
Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.
Ginger Chao (2004)
Role of PD-1 during effector CD8 T cell differentiation
Eunseon Ahn (2018)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.
L. McLane (2019)
PSGL-1 Regulates the Migration and Proliferation of CD8+ T Cells under Homeostatic Conditions
Krystle M. Veerman (2012)
Rapid Fine Conformational Epitope Mapping Using Comprehensive Mutagenesis and Deep Sequencing*
Caitlin A. Kowalsky (2015)
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
L. Wang (2014)
Directed evolution of high-affinity antibody mimics using mRNA display.
Lihui Xu (2002)
Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice
PA Sergent (2018)
P-Selectin Glycoprotein Ligand-1 Negatively Regulates T-Cell Immune Responses1
M. Matsumoto (2009)
Functional Role of P-Selectin Glycoprotein Ligand 1/P-Selectin Interaction in the Generation of Tolerogenic Dendritic Cells1
A. Urzainqui (2007)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
Development of an Autoimmune Syndrome Affecting the Skin and Internal Organs in P‐Selectin Glycoprotein Ligand 1 Leukocyte Receptor–Deficient Mice
A. Pérez-Frías (2014)
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
K. W. Yoon (2015)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
D. Flies (2011)
Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
Nishant Mehta (2019)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis
N. Li (2017)
Ligand-based receptor identification on living cells and tissues using TRICEPS
Andreas P. Frei (2013)
This paper is referenced by
Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy
J. Xu (2020)
Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets.
L. F. Campesato (2020)
Revealing the functional roles of tyrosine sulfation using synthetic sulfopeptides and sulfoproteins.
Joshua W C Maxwell (2020)
Expression of the immune checkpoint VISTA in breast cancer
Liju Zong (2020)
VISTA: Coming of age as a multi‐lineage immune checkpoint
Mohamed A. ElTanbouly (2020)
An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
Nishant Mehta (2020)
High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer
Liju Zong (2020)
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Yolla Haibe (2020)
Cytokines and Co-stimulation in Acute Graft-versus-Host Disease.
G. R. Hill (2020)
Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of skin macrophages in Vsir-/- murine psoriasis
Chenxin Qie (2020)
T-cells produce acidic niches in lymph nodes to suppress their own effector functions
Hao Wu (2020)
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Geng Wang (2020)
FOXD3 Regulates VISTA Expression in Melanoma
Sheera R Rosenbaum (2020)
Mechanisms of immune escape in the cancer immune cycle.
S. Tang (2020)
Emerging immunotherapy targets in lung cancer
Hao-Hua Zhu (2020)
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
A. Naik (2020)
Metabolism of immune cells in cancer
Robert D Leone (2020)
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Jackie E. Bader (2020)
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
Michael F. Coleman (2020)
Enforcing T cell innocence
C. Brown (2020)
Co-inhibitory receptors, transcription factors and tolerance.
A. Mohammadzadeh (2020)
Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019)
Qiaohong Geng (2020)
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation
M. Borggrewe (2020)
Revisiting Immunotherapy: A Focus on Prostate Cancer
Ha-Ram Cha (2020)
Therapeutic Development of Immune Checkpoint Inhibitors.
Jilin Wang (2020)
New emerging targets in cancer immunotherapy: the role of VISTA
M. Tagliamento (2020)
Acidity changes immunology: a new VISTA pathway
K. Mahoney (2019)
Alternative Checkpoints as Targets for Immunotherapy
Ayush Pant (2020)
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Natália Rodrigues Mantuano (2020)
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
S. Ngiow (2020)
Rational Cancer Treatment Combinations: An Urgent Clinical Need.
J. Boshuizen (2020)